Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir i...

ver descrição completa

Detalhes bibliográficos
Autores: Buxeda, A, Arias-Cabrales, C, Perez-Saez, MJ, Cacho, J, Pelegrin, SC, Melilli, E, Aladren, MJ, Galeano, C, Lorenzo, I, Mazuecos, A, Saura, IM, Franco, A, Ruiz-Fuentes, MD, Sanchez-Camara, LA, Siverio, O, Martin, ML, Gonzalez-Garcia, E, Lopez, V, Martin-Moreno, PL, Moina, I, Berrio, EM, Moreso, F, Portoles, JM, Santana-Estupinan, R, Zarraga, S, Canal, C, Sanchez-Alvarez, E, Pascual, J, Crespo, M, Spanish Soc Nephrology COVID-19 Gr
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2021
País:España
Recursos:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositório:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p7640
Acesso em linha:https://isabial.portalinvestigacion.com/publicaciones7640
Access Level:Acceso aberto
Palavra-chave:acute kidney injury
immunosuppression
kidney transplantation
remdesivir
SARS-CoV2l
Descrição
Resumo:Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged >= 65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.

Registros relacionados